TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00923273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: PET CT will be performed at baseline and after two cycles of treatment.
Study: NCT00777686

Intervention type: PROCEDURE
Intervention: MRI/MRS Scan
Description: MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
Study: NCT01358006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40411813
Description: Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
Study: NCT01095328

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: screening
Description: screening for Q-fever with a single blood sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: screening
Description: screening for Q-fever with a single blood sampling
Study: NCT02508506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Single dose, given orally
Study: NCT01878175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Movement Retraining
Description: 15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
Study: NCT00004205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Letrozole 2.5 mg daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily oral administration.
Study: NCT03388554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Study: NCT02617199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesia
Description: ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
Study: NCT01551485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pacebo tablet, blinded given on the first night after surgery
Study: NCT00955344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eToolbox
Description: Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no link to eToolbox
Description: Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
Study: NCT00923273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: PET CT will be performed at baseline and after two cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: PET CT will be performed at baseline and after two cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: PET CT will be performed at baseline and after two cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: PET CT will be performed at baseline and after two cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT04033380

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin blocs (Grandio Blocs, VOCO)
Description: composite-base bloc (Grandio Blocs, VOCO)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ceramic (Suprinity, VITA)
Description: glass ceramic zirconia enhanced lithium silicate glass ceramics (Suprinity, VITA)
Study: NCT04341025

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness based psychosexual therapy ( MBPST)
Description: The group treatment sessions will integrate empirically supported elements of psychoeduation, cognitive behavioural therapy, and mindfulness skills. Each of the six sessions will follow the well-defined manualized treatment protocol. The treatment is adapted from the study team's previous mindfulness-based treatment group (H15-03172), for situational ED which has been shown to be effective. Participants will be provided with handouts and asked to complete approximately 10-60 minutes/day of at-home practice/skills, which may include reading material, mindfulness exercises, and/or behavioural exercises between sessions. During the 2 follow-up sessions, participants will be invited to share their experience since the conclusion of group, ask questions, and participate in troubleshooting.
Study: NCT00923273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study: NCT01318421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND002
Study: NCT02798640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Celliant
Description: 100% Celliant garment

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control Garment
Study: NCT00948714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach Phone Calls
Description: Subjects will receive 3 phone calls from a trained peer coach over 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Educator Visits
Description: Subjects will meet 2 times with a trained health educator in the practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written materials
Description: Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
Study: NCT00249652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAP
Description: 12-session motivational interviewing-based telephone intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: TAU
Description: The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
Study: NCT00948714

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written materials
Description: Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
Study: NCT03175952

Intervention type: DIAGNOSTIC_TEST
Intervention: virtual histology intravascular ultrasound
Description: Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
Study: NCT01074840

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peanut flour
Description: Peanut-allergic subjects will be given peanut flour in increasing amounts.
Study: NCT04272762

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoablation
Description: Pulmonary vein isolation with cryoablation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo procedure
Study: NCT00923624

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: attention control
Description: 9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
Study: NCT00923273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT00923624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adherence intervention
Description: 9 messages tailored by the study nurse and guided by the IMB model
Study: NCT03233672

Intervention type: RADIATION
Group type: OTHER
Intervention: Hypo-fractionated postoperative IMRT-SIB
Description: intensity-modulated radiation treatment with simultaneous integrated boost
Study: NCT02431793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMC2 Strategy
Description: Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMC2 Strategy
Description: Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated message and (c-3) pharmacists prompted to counsel via request printed on prescription.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Reminders
Description: In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
Study: NCT00435929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 1000mg po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir [Invirase]
Description: 1000mg po bid
Study: NCT03474237

Intervention type: OTHER
Intervention: Hormone study and Imaging study
Description: 1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging

Intervention type: OTHER
Intervention: Hormone study and Imaging study
Description: 1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging

Intervention type: OTHER
Intervention: Hormone study and Imaging study
Description: 1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging

Intervention type: OTHER
Intervention: Hormone study and Imaging study
Description: 1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging

Intervention type: OTHER
Intervention: Hormone study and Imaging study
Description: 1. Blood (basal hormone and follow up hormone study)~2. Imaging examination including computed tomography scan or magnetic resonance imaging
Study: NCT02748785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be continued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be continued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be continued

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be continued

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza vaccine
Description: all subjects will be vaccinated with a seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza vaccine
Description: all subjects will be vaccinated with a seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza vaccine
Description: all subjects will be vaccinated with a seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza vaccine
Description: all subjects will be vaccinated with a seasonal influenza vaccine
Study: NCT02410746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: targeted chirocaine pec block
Description: 10ml 0.25% chirocaine in a specifically targeted in a nerve block

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard chirocaine infiltration
Description: 10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard post-operative analgesia
Description: A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard post-operative analgesia
Description: A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
Study: NCT00854685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 3.0mg/kg s.c. - weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 3.0mg/kg s.c. - fortnightly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 1.5mg/kg s.c. - weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART621
Description: 1.5mg/kg s.c. - fortnightly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. - weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. - fortnightly
Study: NCT00462488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicinium
Description: Intravesical administration of Vicinium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicinium
Description: Intravesical administration of Vicinium
Study: NCT01708915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicoboxil
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo matching nonivamide + nicoboxil
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonivamide + nicoboxil (Finalgon)
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonivamide
Description: 2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
Study: NCT00590941

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Blood draw
Description: Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
Study: NCT00262561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: The effect of Aspirin on platelet function was assessed.
Study: NCT00733473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 0.5 mg/ml nebules
Description: Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: % 0.9 Saline solution
Description: Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
Study: NCT03163940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Yoga
Description: A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
Study: NCT03592927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask
Study: NCT03140722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vadadustat
Description: vadadustat
Study: NCT00923273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Study: NCT04017780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-Limb Turbine-Driven Ventilator
Description: Non invasive ventilation performed with a single limb circuit and intentional leak (vented mask) delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Limb Intensive Care Unit ventilator
Description: Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a pediatric/neonatal intensive care unit ventilator (Babylog VN500, Draeger).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double-Limb Turbine-Driven Ventilator
Description: Non invasive ventilation performed with a double limb circuit and expiratory valve incorporated in the ventilator, delivered with a turbine-driven ventilator (Astral 150 \[ResMed\]).
Study: NCT00824889

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood
Study: NCT03188341

Intervention type: OTHER
Intervention: vascular surgery procedure
Description: * an elective open vascular surgery procedure~* ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)
Study: NCT02381470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: Faropenem 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Description: Amoxicillin 500mg/ clavulanic acid 125mg
Study: NCT00824889

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy and sample of blood
Description: Biopsy and sample of blood
Study: NCT04313777

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.
Study: NCT02381470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Description: Amoxicillin 500mg/ clavulanic acid 125mg
Study: NCT04313777

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: Four weeks of cardiac rehabilitation conducted in an outpatient care facility. Three times per week (80 minutes per day) cardiologically monitored aerobic training consisting of: 40 minutes of interval training on a cycloergometer and 40 minutes of general fitness exercises.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapeutic support
Description: 8 sessions of VR therapy (each of them 20 minutes long). As a virtual reality source, VR Tier One device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schultz Autogenic Training
Description: 8 sessions of Schultz Autogenic Training (each of them 20 minutes long).